Publications
The economic burden of overweight and obesity in Europe
24 September 2026
The Issue: Obesity is a chronic disease and a risk factor for serious…
Unlocking the broader value of biologic therapies through biosimilar-enabled access and repositioning
23 September 2026
Biologic medicines account for over 40% of global pharmaceutical spend. When…
Addressing the systemic challenges of underinvestment in prevention
8 June 2026
Prevention of ill-health is an underexploited tool for protecting health systems…
The impact of inflation on incremental costs in HTA
4 June 2026
Inflation reshapes the economic landscape in which new treatments are evaluated.…
Insights
Around the World in HTAs: Zimbabwe – Seizing a window of opportunity
24 September 2026
Zimbabwe has an opportunity to embed health technology assessment (HTA) into its…
Five unanswered questions from the UK’s Renewed Women’s Health Strategy
16 September 2026
The UK’s Renewed Women’s Health Strategy sets out an ambitious plan. But can…
Compared to what? How the choice of comparator affects new medicines
14 September 2026
Comparator choice shapes health technology assessment: it sets the benchmark a…
Why President Trump’s generic drug tariffs are unlikely to fix America’s supply problem
13 August 2026
America's dependence on foreign generic manufacturing is a real national…
Robust analysis, real-world problems
OHE research supports pragmatic solutions and stronger policy decisions
Areas of expertise
OHE’s expertise covers a wide range of topics
Health Technology Assessment (HTA)
Around the World in HTAs: Zimbabwe – Seizing a window of opportunity
Zimbabwe has an opportunity to embed health technology assessment (HTA) into its health system as it works towards…
Unlocking the broader value of biologic therapies through biosimilar-enabled access and repositioning
Biologic medicines account for over 40% of global pharmaceutical spend. When originator patents expire, biosimilar…
Drug Development/R&D
Is the revised Congressional Budget Office model of new drug development fit for purpose?
As U.S. drug-pricing policy changes accelerate, policymakers need reliable ways to understand how reduced pharmaceutical…
Evaluating novel antimicrobials within EU joint clinical assessments
Antimicrobial resistance (AMR) is a growing global health and economic threat. It is responsible for an additional 9.5…
Prevention
Five unanswered questions from the UK’s Renewed Women’s Health Strategy
The UK’s Renewed Women’s Health Strategy sets out an ambitious plan. But can the NHS deliver it?
The cost of inaction on LDL cholesterol
This Insight is based on the WHA79 panel discussion "Lowering Cholesterol, Increasing Impact: The Case for Earlier Action…
EQ-5D and PROMs
Seven reflections on the UK EQ-5D-5L value set – and what comes next
The long-awaited UK EQ-5D-5L value set has been published, marking a key moment for health technology assessment. Its…
Understanding the preferences of people with acute leukemia for different health outcomes
When we want to understand or measure someone’s “health-related quality-of-life”, we typically ask them to describe…
Events
OHE events sharing innovation and insights
OHE Annual Lecture 2026 | Paying for prevention: the global health financing challenge
6 October 2026, 6:00pm
Health systems worldwide spend billions treating diseases that could have been prevented for a fraction of the cost, yet…
